Innovate Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company's lead product candidate is INN-202 that has completed Phase 2b clinical trial for the treatment of celiac disease. It also develops INN-108, which has completed Phase 1 clinical trial to treat mild-to-moderate ulcerative colitis; INN-217 for the treatment of non-alcoholic steatohepatitis and microbiome; and INN-289 to treat crohn's disease. In addition, the company holds global rights for INN-329, a formulation of secretin that is used to enhance visualization in magnetic resonance cholangiopancreatography procedures that is in Phase 3 clinical trial. Innovate Biopharmaceuticals, Inc. is based in Raleigh, North Carolina.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:INNT
CUSIPN/A
Phone919-275-1933
Debt
Debt-to-Equity RatioN/A
Current Ratio1.46
Quick Ratio1.46
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$1.88 million
Price / Sales109.20
Cash FlowN/A
Price / CashN/A
Book Value($1.37) per share
Price / Book-5.81
Profitability
EPS (Most Recent Fiscal Year)N/A
Net Income$-7,920,000.00
Net Margins-166.63%
Return on Equity-1,098.06%
Return on Assets-304.41%
Miscellaneous
Employees8
Outstanding Shares25,790,000
Market Cap$178.96 million
Innovate Biopharmaceuticals (NASDAQ:INNT) Frequently Asked Questions
What is Innovate Biopharmaceuticals' stock symbol?
Innovate Biopharmaceuticals trades on the NASDAQ under the ticker symbol "INNT."
How were Innovate Biopharmaceuticals' earnings last quarter?
Innovate Biopharmaceuticals Inc (NASDAQ:INNT) posted its earnings results on Wednesday, August, 15th. The company reported ($0.16) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.21) by $0.05. Innovate Biopharmaceuticals had a negative return on equity of 1,098.06% and a negative net margin of 166.63%. View Innovate Biopharmaceuticals' Earnings History.
When is Innovate Biopharmaceuticals' next earnings date?
What price target have analysts set for INNT?
2 analysts have issued twelve-month price targets for Innovate Biopharmaceuticals' stock. Their predictions range from $35.00 to $35.00. On average, they expect Innovate Biopharmaceuticals' share price to reach $35.00 in the next year. This suggests a possible upside of 339.7% from the stock's current price. View Analyst Price Targets for Innovate Biopharmaceuticals.
What is the consensus analysts' recommendation for Innovate Biopharmaceuticals?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Innovate Biopharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Innovate Biopharmaceuticals.
Who are some of Innovate Biopharmaceuticals' key competitors?
Some companies that are related to Innovate Biopharmaceuticals include NuCana (NCNA), Epizyme (EPZM), AMAG Pharmaceuticals (AMAG), Flexion Therapeutics (FLXN), Urogen Pharma (URGN), Insys Therapeutics (INSY), Dova Pharmaceuticals (DOVA), CymaBay Therapeutics (CBAY), Obseva (OBSV), Kura Oncology (KURA), Vectura Group (VEGPF), Verastem (VSTM), Basilea Pharmaceutica (BPMUF), ChemoCentryx (CCXI) and ANI Pharmaceuticals (ANIP).
Who are Innovate Biopharmaceuticals' key executives?
Innovate Biopharmaceuticals' management team includes the folowing people:
- Mr. Sandeep Laumas M.D., Exec. Chairman (Age 49)
- Dr. Christopher P. Prior, CEO & Director (Age 65)
- Mr. Jay P. Madan M.S., Pres, Chief Bus. Officer, Interim Principal Financial & Accounting Officer and Director (Age 52)
- Dr. June S. Almenoff, COO & Chief Medical Officer (Age 61)
- Jerry Gardner M.D., Head of Clinical Strategy
Who are Innovate Biopharmaceuticals' major shareholders?
Innovate Biopharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (3.43%), Bank of America Corp DE (0.24%), Bank of New York Mellon Corp (0.15%), Bank of New York Mellon Corp (0.15%), Schwab Charles Investment Management Inc. (0.13%) and Northern Trust Corp (0.09%). Company insiders that own Innovate Biopharmaceuticals stock include Christopher P Prior, June Sherie Almenoff and Sandeep Laumas. View Institutional Ownership Trends for Innovate Biopharmaceuticals.
Which institutional investors are buying Innovate Biopharmaceuticals stock?
INNT stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Bank of America Corp DE, Bank of New York Mellon Corp, Bank of New York Mellon Corp, Schwab Charles Investment Management Inc., Northern Trust Corp and Rhumbline Advisers. Company insiders that have bought Innovate Biopharmaceuticals stock in the last two years include Christopher P Prior, June Sherie Almenoff and Sandeep Laumas. View Insider Buying and Selling for Innovate Biopharmaceuticals.
How do I buy shares of Innovate Biopharmaceuticals?
Shares of INNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Innovate Biopharmaceuticals' stock price today?
One share of INNT stock can currently be purchased for approximately $7.96.
How big of a company is Innovate Biopharmaceuticals?
Innovate Biopharmaceuticals has a market capitalization of $178.96 million and generates $1.88 million in revenue each year. Innovate Biopharmaceuticals employs 8 workers across the globe.
What is Innovate Biopharmaceuticals' official website?
How can I contact Innovate Biopharmaceuticals?
Innovate Biopharmaceuticals' mailing address is 8480 HONEYCUTT ROAD SUITE 120, RALEIGH NC, 27615. The company can be reached via phone at 919-275-1933 or via email at [email protected]
MarketBeat Community Rating for Innovate Biopharmaceuticals (NASDAQ INNT)
MarketBeat's community ratings are surveys of what our community members think about Innovate Biopharmaceuticals and other stocks. Vote "Outperform" if you believe INNT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INNT will underperform the S&P 500 over the long term. You may vote once every thirty days.
